<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166865</url>
  </required_header>
  <id_info>
    <org_study_id>lcsrmyygk</org_study_id>
    <nct_id>NCT03166865</nct_id>
  </id_info>
  <brief_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaocheng People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is one of the most common joint diseases that is considered a chronic
      degenerative disorder. There is no effective therapy available today. This prospective
      clinical trial is designed in an attempt to study the efficacy of mesenchymal stem cells with
      platelet rich plasma in knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in visual analogue scale (VAS)</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
    <description>Visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in western Ontario and McMaster Universities Osteoarthritis Index score</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
    <description>WOMAC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in knee society score (KSS)</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
    <description>knee society score (KSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in MOS item short from health survey(SF-36)</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
    <description>The MOS item short from health survey(SF-36)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of cartilage defects, thickness of cartilage evaluated by X-ray and MRI</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 of articular cavity fluid</measure>
    <time_frame>Baseline, 1, 3, 6 and 12 weeks</time_frame>
    <description>The IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 of articular cavity fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraarticular injection of hyaluronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical-cord mesenchymal stromal cells (UC-MSCs)</intervention_name>
    <description>Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>intra-articular injection of Hyaluronic Acid</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30-70 years old.

          -  No serious infection, chronic diseases, diabetes and tuberculosis.

          -  Osteoarthritis of the knee with grade1-3 defined by the modified Kellgren-Lawrence
             classification.

          -  Written informed consents were obtained from all subjects.

        Exclusion Criteria:

          -  Pregnant women or cognitively impaired adults.

          -  Inflammatory or post infectious arthritis.

          -  Intra-articular drug injection within the previous 2 months.

          -  Serious medical illness with a life expectancy of less than 1 year.

          -  Prior admission for substance abuse.

          -  Arthroscopy during the previous 6 months.

          -  Systemic autoimmune rheumatic disease.

          -  Poorly controlled diabetes mellitus.

          -  Immunosuppressive or anticoagulant treatments.

          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.

          -  NSAID therapy within 15 days prior to inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawang Wang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Liaocheng People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changhui Zhou, Ph.D.</last_name>
    <phone>86-0635-8272202</phone>
    <email>zhouchanghui008@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liaocheng city people's hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>0635</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhui Zhou, Ph.D.</last_name>
      <phone>86-0635-8272202</phone>
      <email>zhouchanghui008@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis (OA)</keyword>
  <keyword>mesenchymal stem cells(MSC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

